GSK Will Re-Do Phase II Wellbutrin Metabolite Studies At Higher Dose
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GSK will re-do Phase II radafaxine studies following the Wellbutrin metabolite’s failure in depression studies, company says during CNS R&D update. New studies will look at higher doses of the noradrenaline/dopamine reuptake inhibitor. GSK will delay filing for depression until 2007